2025-524486-25-00Not yet recruitingPhase 1
A Multicentre, open label, Phase I-Ib Clinical Trial Combining Melanoma-Specific Peptide Vaccination (UniCanVax) and Anti PD-1 Inhibitor (Nivolumab) in Immune Checkpoint Blockade Refractory Metastatic or Unresectable Stage III/IV Melanoma Patients
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Nov 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 13 Jul 2026
- Start date
- 31 Oct 2026
- Lead sponsor
- Humanitas Mirasole S.p.A.
- Diseases
- Melanoma
- EU CT number
- 2025-524486-25-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 25
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Not yet recruiting |
| IRCCS Istituto Nazionale Tumori Fondazione Pascale | Naples | Italy | Not yet recruiting |
| Istituto Oncologico Veneto | Padova | Italy | Not yet recruiting |
| Azienda Ospedaliera di Perugia | Perugia | Italy | Not yet recruiting |
| Humanitas Mirasole S.p.A. | Rozzano | Italy | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.